Scarica l'app Stockscreener
18.26
1.67%
0.30
Dopo l'orario di chiusura:
18.18
-0.08
-0.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVCR Giù?
Forum
Previsione
Precedente Chiudi:
$17.96
Aprire:
$18
Volume 24 ore:
1.87M
Relative Volume:
1.13
Capitalizzazione di mercato:
$2.11B
Reddito:
$674.41M
Utile/perdita netta:
$-173.05M
Rapporto P/E:
-11.90
EPS:
-1.5343
Flusso di cassa netto:
$-48.07M
1 W Prestazione:
+7.35%
1M Prestazione:
+46.43%
6M Prestazione:
+43.10%
1 anno Prestazione:
-1.51%
Intervallo 1D:
$17.80
$18.67
Intervallo di 1 settimana:
$16.86
$18.67
Portata 52W:
$9.82
$20.06
Novocure Ltd Stock (NVCR) Company Profile
Nome
Novocure Ltd
Settore
Industria
Telefono
44 (0)15 3475 6700
Indirizzo
NO. 4 THE FORUM, ST. HELIER
Compare NVCR vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
18.26 | 2.08B | 674.41M | -173.05M | -48.07M | -1.5343 |
ABT
Abbott Laboratories
|
86.67 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
313.00 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.60 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.64 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.54 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2024-12-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Iniziato | SVB Securities | Outperform |
| 2023-07-31 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2023-05-16 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Reiterato | H.C. Wainwright | Buy |
| 2022-11-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Downgrade | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-08 | Iniziato | Loop Capital | Buy |
| 2022-02-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Aggiornamento | Truist | Hold → Buy |
| 2022-01-03 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-14 | Downgrade | Wedbush | Neutral → Underperform |
| 2021-01-25 | Reiterato | Piper Sandler | Overweight |
| 2020-09-23 | Iniziato | Northland Capital | Outperform |
| 2020-09-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Downgrade | Truist | Buy → Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Perform |
| 2020-05-01 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Aggiornamento | SunTrust | Hold → Buy |
| 2019-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-03-20 | Iniziato | SunTrust | Hold |
| 2018-11-02 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Iniziato | Evercore ISI | Outperform |
| 2018-04-18 | Reiterato | Mizuho | Buy |
| 2018-02-23 | Reiterato | Mizuho | Buy |
| 2017-05-24 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Reiterato | Wedbush | Outperform |
| 2016-01-19 | Iniziato | Barclays | Underweight |
| 2015-12-02 | Iniziato | Deutsche Bank | Hold |
Mostra tutto
Novocure Ltd Borsa (NVCR) Ultime notizie
Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $27 - Moomoo
NovoCure Ltd stock (JE00B6T5S470): Q1 2026 growth meets one?time hit - AD HOC NEWS
NVCR Technical Analysis | Trend, Signals & Chart Patterns | NOVOCURE LTD (NASDAQ:NVCR) - ChartMill
NovoCure Earnings Call Highlights Growth, One-Time Hit - TipRanks
NovoCure LimitedOrdinary Shares (NQ: NVCR - FinancialContent
NovoCure Ltd stock (JE00B6T5S470): mixed Q4 2025 results and new Oppenheimer upgrade draw investor f - AD HOC NEWS
NovoCure (NVCR) Is Up 9.7% After Raising 2026 Revenue Outlook And Posting Stronger Q1 Sales - Sahm
NovoCure Ltd stock (JE00B6T5S470): Up 40% YTD on oncology innovation - AD HOC NEWS
A Look At NovoCure (NVCR) Valuation After Raised 2026 Revenue Guidance And Q1 Beat - simplywall.st
Soleus discloses 10.49M-share stake in NovoCure (NASDAQ: NVCR) - Stock Titan
Oncology Company Given Neutral Rating as Q1/26 Beat Sets Up Catalyst - Streetwise Reports
NovoCure Ltd (MEX:NVCRN) Stock Price & 30 Year Financial Data - GuruFocus
NovoCure Ltd (MEX:NVCRN) DCF Valuation - GuruFocus
NovoCure Ltd (MEX:NVCRN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
NovoCure Ltd (MEX:NVCRN) Stock Earnings Transcripts - GuruFocus
Oncology Co. Tests Advanced Cancer Treatments, Reports Q1 2026 Financial Results - Streetwise Reports
MSN Money - MSN
Why NovoCure (NVCR) Is Up 33.2% After FDA Clears Optune Pax And Guidance Ticks Higher - Sahm
HC Wainwright Estimates NovoCure's Q2 Earnings (NASDAQ:NVCR) - MarketBeat
International Markets and NovoCure (NVCR): A Deep Dive for Investors - Yahoo Finance
Wells Fargo Maintains Novocure(NVCR.US) With Hold Rating, Raises Target Price to $17 - Moomoo
NovoCure’s Optune Pax Win And TRIDENT Data Shape Growth Outlook - Sahm
NovoCure Limited Surges As Guidance Hike Fuels NVCR Rally - timothysykes.com
Here's What Analysts Are Forecasting For NovoCure Limited (NASDAQ:NVCR) After Its First-Quarter Results - Moomoo
NovoCure Limited (NASDAQ:NVCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
NovoCure Ltd (NVCR) Shares Surge 9.3% -- What GF Score of 70 Tel - GuruFocus
NovoCure Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm
NovoCure (NASDAQ:NVCR) Trading 6.8% HigherShould You Buy? - MarketBeat
NVCR Maintained by Evercore ISI Group -- Price Target Raised to $20 - GuruFocus
Evercore Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $20 - Moomoo
NovoCure Ltd (NVCR) Q1 2026 Earnings Call Highlights: Revenue Gr - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
NovoCure Ltd Q1 2026 Financial Results: Revenues, Losses, and Key Forward-Looking Statements - Minichart
NovoCure (NVCR) Earnings Story Centers On 20.6% Revenue Growth Versus Ongoing Losses - simplywall.st
NovoCure Limited Q1 2026 Earnings Call Summary - Yahoo Finance
NovoCure (NASDAQ:NVCR) Announces Earnings Results - MarketBeat
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $48 - Moomoo
NovoCure (NVCR) Q1 2026 Earnings Transcript - The Globe and Mail
NovoCure Limited (NVCR) Reports Strong Q1 2026 Results and FDA A - GuruFocus
Novocure (NVCR) Shares Jump 22% on Strong Q1 Revenue and Raised Outlook - GuruFocus
NovoCure (NASDAQ:NVCR) Shares Gap UpShould You Buy? - MarketBeat
NovoCure: Q1 Earnings Snapshot - theheraldreview.com
NVCR Stock Update: Insights on Current Market Trends - GuruFocus
Novocure (NVCR) Reports Strong Q1 Revenue Growth - GuruFocus
Novocure Jumps On Q1 Revenue Growth; Lifts FY26 Revenue Guidance - RTTNews
NovoCure (NVCR) Q1: EPS -0.62 (miss vs -0.51 est.), Revenue $174 - GuruFocus
NovoCure Shares Rise Following Q1 Financial Results - Moomoo
NovoCure Reports Revenue Growth Driven by New Pancreatic Cancer Therapy - HarianBasis.co
NovoCure Q1 Earnings Call Highlights - MarketBeat
NovoCure Limited 2026 Q1ResultsEarnings Call Presentation (NASDAQ:NVCR) 2026-04-30 - Seeking Alpha
NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Novocure Ltd Azioni (NVCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Novocure Ltd Azioni (NVCR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Leupin Nicolas | Former Chief Medical Officer |
Mar 04 '26 |
Sale |
13.31 |
1,100 |
14,636 |
102,979 |
| Weinberg Uri | Chf Medical and Innovation Ofr |
Mar 04 '26 |
Sale |
13.31 |
6,412 |
85,314 |
267,190 |
| Brackmann Christoph | Chief Financial Officer |
Mar 04 '26 |
Sale |
13.31 |
6,412 |
85,314 |
182,842 |
| Leonard Frank X | Chief Executive Officer |
Mar 04 '26 |
Sale |
13.31 |
5,607 |
74,603 |
493,793 |
| Paravasthu Mukund | Chief Operating Officer |
Mar 05 '26 |
Sale |
13.77 |
43,246 |
595,670 |
72,832 |
| Paravasthu Mukund | Chief Operating Officer |
Mar 04 '26 |
Sale |
13.31 |
5,377 |
71,543 |
116,078 |
| Puri Michal Nath | Chief Human Resources Officer |
Mar 04 '26 |
Sale |
13.31 |
1,100 |
14,636 |
201,322 |
| DOYLE WILLIAM F | Executive Chairman |
Mar 03 '26 |
Sale |
12.98 |
71,887 |
932,883 |
328,397 |
1.27%
2.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):